Edition:
United Kingdom

Axovant Sciences Ltd (AXON.OQ)

AXON.OQ on NASDAQ Stock Exchange Global Select Market

2.45USD
5:04pm BST
Change (% chg)

$-0.01 (-0.41%)
Prev Close
$2.46
Open
$2.47
Day's High
$2.47
Day's Low
$2.41
Volume
41,044
Avg. Vol
785,018
52-wk High
$27.93
52-wk Low
$1.02

Chart for

About

Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer's disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive,... (more)

Overall

Beta: --
Market Cap(Mil.): $758.06
Shares Outstanding(Mil.): 107.53
Dividend: --
Yield (%): --

Financials

  AXON.OQ Industry Sector
P/E (TTM): -- 85.33 32.76
EPS (TTM): -2.09 -- --
ROI: -85.17 2.22 14.61
ROE: -95.04 3.86 16.34

BRIEF-Axovant Sciences Initiated Reduction In Its Workforce

* AXOVANT SCIENCES LTD - ‍ ON FEBRUARY 12, INITIATED A CORPORATE REALIGNMENT THAT INCLUDED A REDUCTION IN ITS WORKFORCE - SEC FILING

14 Feb 2018

Axovant Sciences CEO David Hung resigns, shares tumble

Axovant Sciences Ltd's shares sank 20 percent to an all-time low on Monday after Chief Executive David Hung resigned following 10 months at the biotech firm, during which its lead drug candidate failed two key trials.

12 Feb 2018

UPDATE 2-Axovant Sciences CEO David Hung resigns, shares tumble

* Axovant shares fall 20 percent to record low (Adds quotes from incoming CEO, Roivant founder, background on David Hung; updates stock price)

12 Feb 2018

Drug developer Axovant's CEO, COO step down

Feb 12 Axovant Sciences Ltd on Monday said Chief Executive Officer David Hung had resigned, nearly a year after his appointment.

12 Feb 2018

Competitors

Earnings vs. Estimates